INS and obesity disorder: Our recent study has shown that GREM 1 is increased in the adipose tissue in human obesity and Type 2 diabetes, that it is a secreted antagonist of insulin signaling and action in key metabolic target tissues and that circulating levels tend to be increased in obesity but most prominently in Type 2 diabetes [10].